Acute coronary syndromes in patients who have undergone percutaneous coronary intervention is the subject of the conversation between guest Dr. Gary Mintz, chief medical officer of the Cardiovascular Research Foundation, an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education, and host Dr. Janet Wright. How often do patients who have an acute coronary syndrome have a recurrent event? Their discussion includes protocols, paramaters and outcomes of the PROSPECT trial. The use of ultrasound as well as angiography are also discussed in context to help identify unstable coronary plaques in order to prevent adverse coronary events.
Identifying Unstable Coronary Plaques
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Acute coronary syndromes in patients who have undergone percutaneous coronary intervention is the subject of the conversation between guest Dr. Gary Mintz, chief medical officer of the Cardiovascular Research Foundation, an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education, and host Dr. Janet Wright. How often do patients who have an acute coronary syndrome have a recurrent event? Their discussion includes protocols, paramaters and outcomes of the PROSPECT trial. The use of ultrasound as well as angiography are also discussed in context to help identify unstable coronary plaques in order to prevent adverse coronary events.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Bridging Distances in PAH: Bringing Best Practices to the People Through Telementoring
Updates From the 7th World Symposium Task Force
Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
HF Management for Patients with Comorbid Conditions
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
CETP inhibition: Lessons from two decades of clinical trials
Vorasidenib and mIDH Gliomas: Reviewing the Efficacy Data
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?